UTHR Q4 2025 Earnings
Reported Feb 25, 2026 at 6:32 AM ET · SEC Source
Q4 25 EPS
$7.70
BEAT +8.45%
Est. $7.10
Q4 25 Revenue
$790.2M
MISS 2.18%
Est. $807.8M
vs S&P Since Q4 25
+7.1%
BEATING MARKET
UTHR +11.0% vs S&P +4.0%
Full Year 2025 Results
FY 25 EPS
$27.86
BEAT +3.39%
Est. $26.95
FY 25 Revenue
$3.18B
MISS 0.55%
Est. $3.20B
Market Reaction
Did UTHR Beat Earnings? Q4 2025 Results
United Therapeutics delivered a mixed but ultimately encouraging fourth quarter for fiscal 2025, posting earnings that cleared Wall Street's bar even as revenue fell slightly short. Diluted EPS came in at $7.70, an 8.45% beat against the $7.10 consen… Read more United Therapeutics delivered a mixed but ultimately encouraging fourth quarter for fiscal 2025, posting earnings that cleared Wall Street's bar even as revenue fell slightly short. Diluted EPS came in at $7.70, an 8.45% beat against the $7.10 consensus, while revenue of $790.20 million trailed the $807.78 million estimate by 2.18%, though it still represented a solid 7.4% increase year over year. The primary engine behind the profit strength was the Tyvaso franchise, where Tyvaso DPI surged 24% in the quarter to $338.60 million, fueled by an expanding patient base and a meaningful lift in commercial utilization following Medicare Part D redesign under the Inflation Reduction Act. That momentum helped offset softer results from Remodulin and Unituxin, both of which declined in the period. Looking ahead, enthusiasm is building around ralinepag after the ADVANCE OUTCOMES trial demonstrated a 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension, with management targeting an FDA submission by the second half of 2026 and expressing confidence in sustaining durable double-digit revenue growth.
Key Takeaways
- • Tyvaso DPI volume growth from expanding patient base following product launch
- • Increased commercial utilization following Medicare Part D benefit redesign under the Inflation Reduction Act
- • Orenitram volume growth driven in part by IRA-related utilization increases
- • Net unrealized gains on equity securities boosting other income
UTHR Forward Guidance & Outlook
CEO Martine Rothblatt indicated that the ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock significant new treatment options and launch a period of transformational growth for the company. COO Michael Benkowitz expressed confidence that commercial strength, differentiated therapies, and expanding market opportunities position the company to continue delivering durable double-digit revenue growth.
UTHR YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
UTHR Revenue by Segment
With YoY comparisons, source: SEC Filings
UTHR Revenue by Geography
With YoY comparisons, source: SEC Filings
“As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission.”
— Martine Rothblatt, Q4 2025 Earnings Press Release
UTHR Earnings Trends
UTHR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
UTHR EPS Trend
Earnings per share: estimate vs actual
UTHR Revenue Trend
Quarterly revenue: estimate vs actual
UTHR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $7.10 | $7.70 | +8.45% | $790.2M | -2.18% |
| FY Full Year | $26.95 | $27.86 | +3.39% | $3.18B | -0.55% |
| Q3 25 BEAT | $6.96 | $7.16 | +2.86% | $799.5M | -1.65% |
| Q2 25 MISS | $6.92 | $6.41 | -7.31% | $798.6M | -0.63% |
| Q1 25 BEAT | $6.28 | $6.63 | +5.62% | $794.4M | +9.37% |